Discover how multivariate models use multiple variables for investment forecasting, risk analysis, and decision-making in ...
A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback